ORIGINAL ARTICLE
Potential impact of HercepTest™ mAb PharmDx (Dako Omnis) (ge001) in breast cancer diagnosis
1
Department of Cancer Pathology, Greater Poland Cancer Centre, Poznañ, Poland
2
Department of Tumour Pathology and Prophylaxis, University of Medical Sciences, Poznañ, Poland
Submission date: 2023-05-24
Acceptance date: 2023-06-21
Publication date: 2023-07-10
Corresponding author
Agata Kubicka
Agata Kubicka Department of Cancer Pathology Greater Poland Cancer Centre 15 Garbary St. 61-866 Poznañ, Poland
Agata Kubicka Department of Cancer Pathology Greater Poland Cancer Centre 15 Garbary St. 61-866 Poznañ, Poland
Pol J Pathol 2023;74(2):82-88
KEYWORDS
TOPICS
ABSTRACT
The HER2 gene is a biomarker for breast cancer prognosis and treatment.
Overexpression of HER2 protein determined by immunohistochemistry (IHC) or amplification of the HER2 gene determined by fluorescence in situ hybridization (FISH) is a condition for qualifying patients for anti-HER2 therapy. Due to the high toxicity of anti-HER2 treatment, proper patient selection is essential.
In our study we compared 40 cases with IHC staining of HER2 antibody determined by Ventana PATHWAY anti-HER2/neu antibody (4B5) as HER2 2+ with the new antibody (HercepTest™ mAb PharmDx [Dako Omnis] [GE001]). Then using a double-blind study we compared the (IHC) evaluation with FISH results.
In 65% of cases (26/40) the IHC 2+ score remained unchanged, in 32.5% of cases (13/40) expression of HER2 protein after IHC with new antibody was indicated as 3+ score, and in one case we observed a decrease of HER2 protein expression to 1+. In all cases but one, in which we found IHC HER 3+ with new antibody, there was FISH amplification.
We have reason to believe that the new antibody will reduce the diagnostic time and avoid unnecessary costs. Due to the small study group, further investigation is needed.
Overexpression of HER2 protein determined by immunohistochemistry (IHC) or amplification of the HER2 gene determined by fluorescence in situ hybridization (FISH) is a condition for qualifying patients for anti-HER2 therapy. Due to the high toxicity of anti-HER2 treatment, proper patient selection is essential.
In our study we compared 40 cases with IHC staining of HER2 antibody determined by Ventana PATHWAY anti-HER2/neu antibody (4B5) as HER2 2+ with the new antibody (HercepTest™ mAb PharmDx [Dako Omnis] [GE001]). Then using a double-blind study we compared the (IHC) evaluation with FISH results.
In 65% of cases (26/40) the IHC 2+ score remained unchanged, in 32.5% of cases (13/40) expression of HER2 protein after IHC with new antibody was indicated as 3+ score, and in one case we observed a decrease of HER2 protein expression to 1+. In all cases but one, in which we found IHC HER 3+ with new antibody, there was FISH amplification.
We have reason to believe that the new antibody will reduce the diagnostic time and avoid unnecessary costs. Due to the small study group, further investigation is needed.
REFERENCES (30)
1.
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209-249.
2.
Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: an overview. Int J Cancer 2021; 149: 778-789.
3.
Arnold M, Morgan E, Rumgay H, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast 2022; 66: 15-23.
4.
Aznab M, Izadi B, Amirian F, et al. Comparison of immunohistochemical methods (IHC) and fluorescent in situ hybridization (FISH) in the detection of HER 2/neu gene in Kurdish patients with breast cancer in western Iran. Int J Hematol Oncol Stem Cell Res 2022; 16: 217-223.
5.
DeSantis CE, Fedewa SA, Goding Sauer A, et al. Breast cancer statistics, 2015: convergence of incidence rates between black and white women. CA Cancer J Clin 2016; 66: 31-42.
6.
Ahn S, Won Woo J, Lee K, et al. HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation. J Pathol Transl Med 2020; 54: 34-44.
7.
Kay C, Martínez-Pérez C, Meehan J, et al. Current trends in the treatment of HR+/HER2+ breast cancer. Future Oncol 2021; 17: 1665-1681.
8.
Patel A, Unni N, Peng Y. The changing paradigm for the treatment of HER2-positive breast cancer. Cancers (Basel) 2020; 12: 2081.
9.
Available from: https://www.gov.pl/web/zdrowie...- ministra-zdrowia-z-dnia-20-lutego-2023-r-w-sprawie-wykazu-lekow-srodkow-spozywczych-specjalnego-przeznaczenia-zywieniowego-na-1-marca-2023-r (accessed: 2023-05-06).
10.
Wolff C, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Arch Pathol Lab Med 2018; 142: 1364-1382.
11.
Lim TH, Lim AST, Leng Tien S, et al. Impact of the updated 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines on human epidermal growth factor receptor 2 (HER2) gene testing in invasive breast cancers: a single center study. Ann Diagn Pathol 2022; 58: 151935.
12.
Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-726.
13.
Pernas S, Barroso-Sousa R, Tolaney SM. Optimal treatment of early stage HER2-positive breast cancer. Cancer 2018; 124: 4455-4466.
14.
Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
15.
Ganz PA, Romond EH, Cecchini RS, et al. Long-term follow-up of cardiac function and quality of life for patients in NSABP Protocol B-31/NRG Oncology: a randomized trial comparing the safety and efficacy of doxorubicin and cyclophosphamide (AC) followed by paclitaxel with AC followed by paclitaxel and trastuzumab in patients with node-positive breast cancer with tumors overexpressing human epidermal growth factor receptor 2. J Clin Oncol 2017; 35: 3942-3948.
16.
Chien AJ, Rugo HS. The cardiac safety of trastuzumab in the treatment of breast cancer. Exp Op Drug Safety 2010; 9: 335-346.
17.
Egervari K, Szollosi Z, Nemes Z. Immunohistochemical antibodies in breast cancer HER2 diagnostics. Tumor Biol 2008; 29: 18-27.
18.
Carretero-Barrio I, Caniego-Casas T, Rosas M, et al. Evaluation of ERBB2 mRNA expression in HER2-equivocal (2+) immunohistochemistry cases. Cancers (Basel) 2023; 15: 1688.
19.
Wang M, Ding Q, Gu J, et al. Breast cancer with a HER2 FISH Group 2 result: should HER2 tests be repeated? Clin Breast Cancer 2023: 415-422.
20.
Pauzi SH, Saari HN, Roslan MR, et al. Comparison study of HER2 protein overexpression and its gene status in breast cancer. Malays J Pathol 2019; 41: 133-138.
21.
Marsza³ek A, Krzakowski M. Recommendations for evaluation of predictive marker HER2 in patients with invasive breast cancer. Oncol Clin Pract 2018; 14: 272-277.
22.
Horimoto Y, Ishizuka Y, Ueki Y, et al. Comparison of tumors with HER2 overexpression versus HER2 amplifcation in HER2-positive breast cancer patients. BMC Cancer 2022; 22: 242.
23.
Fitzgibbons PL, Connolly JL. College of American Pathologist (CAP); template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast. Available from: https://www.cap.org/protocols-... (accessed: 2023-05-06).
24.
Seol H, Lee HJ, Choi Y, et al. Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance. Mod Pathol 2012; 25: 938-948.
25.
Meng S, Tripathy D, Shete S, et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A 2004; 101: 9393-9398.
26.
Lower EE, Glass E, Blau R. HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat 2009; 113: 301-306.
27.
Gong Y, Booser DJ, Sneige N. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 2005; 103: 1763-1769.
28.
Layfield LJ, Wallander ML, Tripp SR, et al. Comparison of Dual-ISH (DISH) with fluorescence in situ hybridization (FISH) and correlation with immunohistochemical findings for HER2/neu status in breast carcinoma. Appl Immunohistochem Mol Morphol 2017; 25: 231-236.
29.
Jonjiæ N, Mustaæ E, Tomiæ S, et al. Interlaboratory concordance in HER-2 positive breast canceR. Acta Clin Croat 2015; 54: 479-485.
30.
Fararjeh A, Kaddumi E, Al-Khader A, et al. The significance of StAR-related lipid transfer protein-3 expression in breast cancer. Pol J Pathol 2022; 73: 215-222.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
